相关实验视频

Updated: Jun 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在瘤免疫疗法中准PD-1/PD-L1:与宿主生长调节通路的机制和相互作用

Songyu Shen¹, Yihan Hong¹, Jiajun Huang¹

¹School of life Science, Shanghai University, 99 Shangda Road, 200444, China.

Cytokine & growth factor reviews

|August 23, 2024

概括

瘤免疫疗法,包括向BRAF和PD-1/PD-L1,是新的护理标准. 本综述探讨了向VEGF,EGFR,LAG-3,CTLA-4和BRAF如何影响PD-1/PD-L1表达和新型癌症治疗的生长因子信号.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

瘤免疫疗法是一个快速发展的领域,成为癌症治疗的基石.
像VEGF和EGFR这样的传统目标正在扩大,包括BRAF和PD-1/PD-L1,显示出很大的前景.
了解免疫检查点和生长因子信号之间的相互作用对于有效的治疗至关重要.

研究的目的:

审查调节PD-1/PD-L1表达的疗法的影响和机制.
调查向VEGF,EGFR,LAG-3,CTLA-4和BRAF是如何影响PD-1/PD-L1.1的.
阐明瘤微环境中的免疫调节途径和生长因子网络之间的相互作用.

主要方法:

关于瘤免疫治疗的最新研究的文献综述.
对涉及VEGF,EGFR,BRAF,LAG-3和CTLA-4在调节PD-1/PD-L1.1中的机制的分析.
研究免疫检查点和生长因子信号通路之间的交叉声.

主要成果:

针对VEGF,EGFR,BRAF,LAG-3和CTLA-4等特定途径可以显著调节PD-1/PD-L1表达.
这些调制影响瘤微环境中的关键生长因子信号网络.
免疫逃避机制和瘤生长信号之间存在复杂的相互作用.

结论:

针对PD-1/PD-L1与VEGF,EGFR,BRAF,LAG-3和CTLA-4等途径一起提供潜在的协同治疗策略.
阐明这些相互作用为开发新的,更有效的癌症免疫疗法提供了基础.
对这些结合方法的进一步研究可能会导致癌症治疗中患者的治疗结果得到改善.

关键词:

这就是BRAF.在 CTLA-4 中.欧洲农业基金会 (EGFR) 是一个基金.现场行动组-3 在PD-1/PD-L1中.治疗目标治疗目标瘤免疫疗法免疫疗法在VEGF中,VEGF是VEGF.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...